Sefpotek

Quick links to important sections

Sefpotek

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sefpotek

Quick Facts: Sefpotek

Property Description
Active ingredient Cefpodoxime (as Cefpodoxime proxetil prodrug)
Form Film-coated tablets and powder for oral suspension
Pharmacological class Beta-Lactam, Third-generation cephalosporin antibiotic
Common use Treatment of infections caused by susceptible bacteria
Origin Semi-synthetic compound

What Type of Medicine is Sefpotek?

Sefpotek is a prescription-only antibacterial medicine that belongs to the class of Beta-Lactam antibiotics, specifically identified as a third-generation cephalosporin. This pharmacological classification denotes its specific chemical structure and its broad spectrum of activity. The active component is the substance Cefpodoxime, which is supplied as the prodrug Cefpodoxime proxetil. This is a semi-synthetic compound designed to enhance the absorption of the active drug when administered via the oral route of administration. The prodrug is efficiently converted into the biologically active Cefpodoxime within the body to initiate its therapeutic effect.


What is Cefpodoxime and How Does it Fight Infection?

Cefpodoxime is the single active ingredient responsible for Sefpotek's core purpose: the elimination of harmful bacteria through a process called bactericidal action. The medicine functions by specifically interfering with the processes necessary for bacteria to build and maintain their protective cell walls, which is essential for microbial survival. The bactericidal activity results from its inhibition of bacterial cell wall synthesis. This scientific conclusion confirms that the medicine works by actively killing the bacteria causing the infection.

The general therapeutic purpose of this precise action is to control and resolve bacterial infections caused by susceptible microorganisms. Cefpodoxime proxetil demonstrates clinically recognized efficacy in patients with infections commonly affecting the respiratory or urinary tract. This finding supports the medicine's general role in clearing bacterial illnesses in a reliable manner.


Available Forms: Tablets and Oral Suspension

Sefpotek is supplied as a single-entity product in two distinct pharmaceutical preparations for oral intake: film-coated tablets and a powder for oral suspension. The distinction between these forms is crucial for maximizing patient suitability and ease of delivery. The film-coated tablets are typically intended for adult patients. In contrast, the powder for oral suspension is designed to be reconstituted into a liquid, which facilitates accurate delivery and administration, particularly for pediatric patients and others who have difficulty swallowing pills, ensuring therapeutic access across different target audiences.

Regulatory References

  1. Cefpodoxime Proxetil (DailyMed)

What side effects are possible with Sefpotek?

Possible Side Effects and Safety Information

The safety profile of Cefpodoxime proxetil (Sefpotek) is organized in regulatory documents according to the frequency and type of possible effects. The most frequently documented events fall under Gastrointestinal Disorders.


Adverse Reaction Classification (Official Regulatory Tiers)

Classification Examples of Officially Documented Effects
Common Diarrhea, abdominal pain, nausea, vomiting, headache, dizziness, and rash.
Uncommon Pruritus (itching), urticaria, and tinnitus.
Rare/Very Rare Haematological changes (e.g., leucopenia, thrombocytopenia), severe skin reactions, and anaphylactic reactions.

Serious Adverse Reactions and Safety Constraints

Official regulatory labels explicitly document several serious adverse reactions, including potentially life-threatening severe hypersensitivity reactions (anaphylaxis) and Clostridium difficile-associated diarrhea (CDAD). These risks are inherent to the antibiotic class.

Sefpotek is contraindicated in individuals with a known history of severe immediate-type hypersensitivity reaction to any cephalosporin or other beta-lactam antibiotic. The regulatory text also notes that specific clinical consideration is necessary for patients with renal impairment due to the potential for prolonged drug concentrations, and that the drug is excreted in human milk.

Exposure-related safety notes caution that symptoms of CDAD may occur even after the medicine has been discontinued, and prolonged use may result in the overgrowth of non-susceptible organisms. The regulatory profile is structured to clearly define the official safety boundary of the drug, establishing the risk framework without providing clinical advice.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Sefpotek (Cefpodoxime proxetil) is officially documented to present primarily with gastrointestinal disturbances. These manifestations commonly include nausea, vomiting, diarrhea, and epigastric distress.

The official profile also notes the potential for severe, life-threatening neurological outcomes, such as seizure (convulsions) and encephalopathy. These serious manifestations are a particular risk for patients with moderate to severe renal impairment because reduced drug elimination can lead to high and prolonged serum concentrations of Cefpodoxime. Close monitoring of renal function is advised in such situations.

Mandatory Emergency Actions

Immediate medical attention must be sought if an overdose is suspected. Regulatory guidance states that emergency services must be contacted immediately if the person has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. The Poison Control Center should also be contacted.

No specific antidote is documented. Management focuses on supportive and symptomatic therapy, which may include gastric lavage. For a serious toxic reaction, hemodialysis or peritoneal dialysis may be employed to help remove the drug from the body, especially when kidney function is compromised.

Therapeutic Uses of Sefpotek

What Sefpotek Treats: Main Uses and Benefits

Sefpotek is applied across domains where additional symptomatic support is needed to help manage symptoms associated with bacterial infections. It is commonly used when conditions present with a significant symptomatic burden, such as those related to community-acquired pneumonia, acute exacerbations of chronic bronchitis, uncomplicated urinary tract infections, and various skin or soft tissue infections. The primary benefit is supportive relief that helps ease the overall symptom load during difficult episodes.


Easing Symptom Clusters and Functional Strain

Sefpotek is relevant in clinical settings that involve acute or unstable symptom patterns and conditions characterized by periods of heightened physiological activity. It helps address groups of symptoms that may become intense or disruptive and create noticeable functional strain. “It provides support that helps ease the overall burden of symptoms, contributing to improved comfort during symptomatic periods.”

Quick Fact: Supports Management of Heightened Discomfort

Sefpotek may assist with managing discomfort and other symptoms linked to common infections like bronchitis, sinusitis, tonsillitis, and conditions presenting with systemic or localized discomfort.

Regulatory References

  1. Cefpodoxime Proxetil full prescribing information, U.S. National Library of Medicine (DailyMed)

Eligibility and Restrictions for Use

Who can and cannot use Sefpotek?

Eligibility for Sefpotek (Cefpodoxime proxetil) is strictly determined by regulatory documentation concerning patient history and physiological status.

Contraindications and Non-Eligibility

Sefpotek is contraindicated in patients with a known hypersensitivity to Cefpodoxime, any other cephalosporin antibiotic, or a severe allergic history involving penicillin or other β-Lactam antibiotics due to cross-sensitivity risk. Use is not established and not recommended for infants younger than 2 months of age.

Conditional Use and Restrictions

Population Group Regulatory Status
Renal Impairment Restricted Use: Patients with moderate or severe renal impairment require mandatory dosage adjustment due to reduced drug elimination.
Hemodialysis Restricted Use: Dose frequency must be adjusted.
Pregnancy Conditional Use: Classified as Category B; permitted only if clearly needed as adequate controlled studies in pregnant women are lacking.
Lactation Conditional Use: Cefpodoxime is excreted in milk; a decision to discontinue nursing or the drug must be made.
Older Adults Caution Required: No specific age-related dosage modification is necessary if renal function is normal, but caution is advised due to the higher prevalence of diminished renal function.

Hepatic Impairment does not require dosage adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several categories of products that may interact with Sefpotek (Cefpodoxime proxetil), requiring specific clinical considerations.

Pharmacokinetic Interactions

The following products alter the systemic exposure of Sefpotek:

  • Acid-Reducing Agents: Medicines that decrease stomach acid, such as antacids (e.g., aluminum hydroxide) and H2-receptor antagonists (e.g., cimetidine, ranitidine), reduce the absorption of Sefpotek. This interaction may result in subtherapeutic plasma concentrations and is generally restricted for concurrent use to avoid loss of efficacy.
  • Renal Excretion Inhibitors: The drug Probenecid inhibits the renal elimination of Cefpodoxime, leading to significantly increased plasma levels (AUC and peak concentration) of the drug.

Pharmacodynamic Interactions

  • Oral Anticoagulants: Concomitant use with oral anticoagulants, such as warfarin derivatives, requires caution. The combination may increase the anticoagulant effect, necessitating the close monitoring of coagulation parameters in the patient.
  • Nephrotoxic Agents: Due to the potential for cephalosporins to affect renal function, caution and close monitoring of kidney function are advised when Sefpotek is administered alongside other drugs with known nephrotoxic potential, including potent diuretics and aminoglycosides.

Summary of Interaction Constraints

The interaction profile indicates constraints on use with acid-reducing agents due to a reduction in efficacy and mandates increased patient monitoring for those receiving Probenecid, oral anticoagulants, or other nephrotoxic medicines.

Mechanism of Action

The Mechanistic Action of Sefpotek

The mechanism of Cefpodoxime, the active form of Sefpotek, is focused on disrupting the structure of bacterial microorganisms. It achieves this by directly binding to bacterial enzymes called Penicillin-Binding Proteins (PBPs). This binding is irreversible, effectively inhibiting the final stage of cell wall synthesis, known as transpeptidation, which prevents the critical cross-linking of the peptidoglycan polymer. This action is the basis for the drug's bactericidal action.


The molecular inhibition of cell wall assembly initiates an irreversible cascade for the bacteria. The resulting structural defects in the cell wall compromise the bacterium's ability to withstand its own internal osmotic pressure. The cell wall ruptures (lysis), leading to the swift and active destruction of the susceptible microorganism.


This mechanism can be functionally constrained by specific bacterial defenses. Efficacy is limited by bacteria that produce Extended-Spectrum Beta-Lactamases (ESBLs), which chemically inactivate the drug before it can reach the PBPs. Additionally, structural alterations in PBP targets can reduce the drug's binding affinity, limiting the mechanism's inherent activity.

Dosage and Administration Information

How to Use Sefpotek

Sefpotek (Cefpodoxime proxetil) is exclusively used via the oral route of administration, available as both film-coated tablets and a powder for oral suspension. The tablets are typically administered to adults, while the suspension is primarily used for pediatric patients.


Standard Adult Dosing Principles and Frequency

The standard regimen for Sefpotek involves twice-daily (every 12 hours) dosing for most approved indications, ensuring continuous presence of the active drug. The specific dose and treatment length are defined by the condition being addressed:

Condition Typical Dose (per dose) Duration
Pharyngitis/Tonsillitis 100 mg 5 to 10 days
Sinusitis, AECB, Pneumonia 200 mg 10 to 14 days
Uncomplicated Gonorrhea 200 mg Single administration

These regimens reflect the active Cefpodoxime equivalent. The full prescribed course must be completed, even if symptoms subside.


Administration Timing and Adjustments

Administration of the medicine is subject to specific timing instructions. The film-coated tablets must be taken with food to enhance drug absorption. In contrast, the reconstituted oral suspension may be taken without regard to meals.

Dosage interval adjustments are necessary for patients with reduced kidney function. For individuals with severe renal impairment (creatinine clearance <30 mL/min), the dosing frequency is reduced to once every 24 hours instead of the standard every 12 hours. Pediatric dosing is determined by body weight (5 mg/kg per dose) administered every 12 hours, up to a maximum dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus: Acute Conditions

Clinical research has investigated the drug's activity in controlling specific bacterial infections. These studies primarily included randomized, controlled trials.

  • Acute Respiratory Infections: Researchers examined the drug's use for upper respiratory tract infections, such as acute maxillary sinusitis and tonsillopharyngitis, in adult populations. One study reported high rates of clinical resolution and improvement in related signs and symptoms.
  • Urinary Tract Infections (UTIs): Controlled trials have evaluated the drug in patients with uncomplicated UTIs. These trials generally focused on measuring the rate of bacterial eradication and the associated clinical outcomes over the treatment period.

Research Focus: Antibacterial Activity

As a third-generation cephalosporin, the drug's activity was examined against a broad range of Gram-positive and Gram-negative bacteria. Studies on its mechanism of action focus on its ability to inhibit bacterial cell wall synthesis. The drug is reported to retain stability in the presence of certain beta-lactamase enzymes produced by some resistant bacteria.

Research Focus: Tolerability Data

Studies collected data on adverse events to assess tolerability and safety for use in adults. The clinical trials recorded the frequency and severity of adverse events, including gastrointestinal effects such as nausea, vomiting, and diarrhea.

Specific Patient Groups

Research has explored the drug's metabolism in patients with mild to moderate liver impairment. Patients with severe renal impairment were typically excluded from major efficacy trials, with pharmacokinetic studies suggesting dose adjustment may be necessary in those with reduced kidney function.

Frequently Asked Questions (FAQ)

Common questions about Sefpotek (FAQ)


Q: How quickly does Sefpotek start to work after taking it?

A: According to pharmacokinetic information, the active drug from Sefpotek, called Cefpodoxime, typically reaches its highest concentration in your bloodstream approximately 2 to 3 hours after administration of the oral tablet. This time point represents when the active drug concentration is highest in the bloodstream, often correlating with its greatest activity against susceptible bacteria.


Q: How long does the effect of Sefpotek last in the body?

A: Regulatory information indicates that the active drug, Cefpodoxime, has an elimination half-life (Tfrac12) ranging from about 2.09 to 2.84 hours in patients with normal kidney function. This measure shows the typical rate at which the drug concentration is reduced in the body.


Q: What should I do if I forget to take my Sefpotek dose?

A: Official guidelines advise taking the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed one is generally skipped. Regulatory information cautions against taking a double dose to make up for a single missed dose.


Q: Why is it important to finish the whole course of Sefpotek?

A: Regulatory documents emphasize that completing the entire prescribed course of Sefpotek is a standard requirement to help ensure the infection is effectively managed. This practice helps to reduce the development of drug-resistant bacteria that might otherwise survive incomplete treatment.


Q: Can Sefpotek cause yeast infections?

A: Like many antibiotics, Sefpotek may cause a disruption in the body's natural balance of microorganisms. Official safety information indicates this can result in the overgrowth of non-susceptible organisms, which includes reports of vulvovaginal fungal (yeast) infections.


Q: Does Sefpotek interact with pain relievers like ibuprofen or acetaminophen?

A: The official product labeling for Sefpotek specifies interactions with certain antacids and blood thinners, but it does not explicitly list interactions with common non-prescription pain relievers like acetaminophen or ibuprofen. Patients should always inform their healthcare provider about all medications and supplements they are currently taking.


Q: Can Sefpotek affect blood sugar levels?

A: Official labeling notes that Cefpodoxime may cause inaccurate results, specifically a false-positive reaction, in certain types of urine glucose tests that rely on reducing substances. If blood sugar is being monitored, healthcare providers often recommend using enzymatic glucose oxidase methods to ensure accurate readings.


Q: Does Sefpotek make you sensitive to the sun?

A: While some antibiotics are known to cause photosensitivity (increased sun sensitivity), the official safety labels for Cefpodoxime do not typically list this as a common or frequently reported adverse reaction.


Q: What kind of infections is Sefpotek typically prescribed for?

A: Regulatory documents specify that Sefpotek is approved to treat infections caused by susceptible bacteria. These commonly include specific types of pneumonia, sinusitis, tonsillitis/pharyngitis, skin and skin structure infections, uncomplicated urinary tract infections (UTIs), and gonorrhea.


Q: Can Sefpotek treat a viral infection, or is it just for bacteria?

A: Sefpotek is classified as an antibacterial medicine, meaning its mechanism is specifically designed to target and kill susceptible bacteria. Regulatory guidelines confirm that it is not effective against viral infections, such as the common cold or influenza.


Q: Is it normal to feel tired or dizzy while taking Sefpotek?

A: Dizziness is officially listed as a common adverse reaction in safety data for Sefpotek. Fatigue (general tiredness) is also reported, though it is considered a less common side effect. Any concerning symptoms should be discussed with a healthcare provider.


Q: Does Sefpotek need to be taken with food?

A: Official administration instructions specify that the tablets should be taken with food to enhance drug absorption. Conversely, the liquid oral suspension may be taken without regard to meals, offering more flexibility.


Q: Can Sefpotek affect birth control pills?

A: Some regulatory resources suggest that antimicrobial agents like Cefpodoxime may theoretically impair the effectiveness of estrogen-containing oral contraceptives. Patients with concerns about the effectiveness of contraceptives while using this medication should speak to a healthcare professional for specific guidance.


Q: Can Sefpotek be used during pregnancy or while breastfeeding?

A: For pregnancy, the drug is Category B and should only be used if a healthcare provider determines it is clearly needed. For breastfeeding, the drug passes into human milk, meaning a decision regarding whether to temporarily stop nursing or discontinue the drug must be made in consultation with a healthcare provider.


Q: Is Sefpotek known to interact with blood thinners?

A: Yes, official drug information indicates that caution is required when Sefpotek is used alongside oral anticoagulants (often called blood thinners), such as warfarin derivatives. This combination may increase the anticoagulant effect, which is why close monitoring of blood coagulation parameters by a healthcare provider may be necessary.


Q: Does Sefpotek come in different strengths?

A: Yes, Sefpotek (Cefpodoxime proxetil) is supplied in multiple forms and strengths. Tablets are available equivalent to 100 mg and 200 mg of the active drug, and the oral suspension is provided in concentrations of 50 mg/5 mL and 100 mg/5 mL.


Q: Is Sefpotek ever used to prevent infections?

A: Regulatory guidelines specify that Sefpotek should be used for the treatment of infections that are proven or strongly suspected to be caused by susceptible bacteria. Its approved purpose is specifically for therapy, and guidelines advise against using it without a confirmed or suspected bacterial cause.


Q: Can Sefpotek cause problems with sleep?

A: Yes, official safety data lists disturbances in sleep as potential adverse effects. Specifically, both insomnia (difficulty sleeping) and, less commonly, nightmares have been reported.


Q: Is it possible to become resistant to Sefpotek over time?

A: All antibacterial drugs carry a risk of contributing to the development of drug-resistant bacteria. The primary way to mitigate this risk is to follow the full course of treatment as prescribed, as emphasized by regulatory guidance.


Q: What does Sefpotek target in bacteria?

A: Cefpodoxime, the active ingredient, works to eliminate susceptible bacteria by inhibiting the final steps in the synthesis of the bacterial cell wall. This action, described as bactericidal, prevents the bacteria from maintaining their essential structure.


Q: Can Sefpotek be used for skin infections?

A: Yes, official documents confirm that Sefpotek is approved for treating specific types of skin and skin structure infections that are known to be caused by susceptible strains of bacteria.


Q: Can Sefpotek cause changes in taste or smell?

A: Yes, official adverse event reports from safety monitoring list taste alteration or loss (known medically as dysgeusia or ageusia) as a possible, though less common, side effect of the medicine.

How should Sefpotek be stored and disposed of?

How to Store and Dispose of Sefpotek (Cefpodoxime Proxetil)

Official guidelines define specific storage and disposal requirements to maintain product integrity and safety.


Storage Requirements

Formulation Required Storage Condition Stability Constraint
Tablets Room Temperature (20°C to 25°C) in the original, tightly closed container. None specified.
Liquid Suspension Refrigeration (2°C to 8°C). Do not freeze. Discard any unused portion after 14 days of preparation.

Both forms must be protected from light, excessive heat, and moisture. It is required to keep Sefpotek out of the reach and sight of children at all times.


Disposal Instructions

Dispose of unused or expired Sefpotek by utilizing an authorized drug take-back program. If a program is unavailable, follow the regulatory instruction to mix the medicine with an undesirable substance (like dirt or coffee grounds) and place the mixture in a sealed container before discarding it in the household trash. Personal information on labels must be scratched out prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sefpotek found in:

A-Z Index: